Global Insight Services have recently published a report on Alzheimer’s Disease – Drug Pipeline Landscape, 2022. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Alzheimer’s disease is a progressive, degenerative brain disorder that attacks the brain’s nerve cells, or neurons, and causes them to waste away. This disease is characterized by a slow, gradual decline in memory, thinking, and reasoning skills. Alzheimer’s is the most common form of dementia, accounting for 60 to 80 percent of all cases. Dementia is a general term for a decline in mental ability severe enough to interfere with daily life.
Alzheimer’s disease is named after German physician Alois Alzheimer. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a patient who had died of an unusual mental illness. He found abnormal clumps (now called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary tangles) among the patient’s brain cells. These discoveries provide some of the first hints about what happens in the brains of people with Alzheimer’s.
Download Sample of Report : https://www.globalinsightservices.com/request-sample/GIS31031
Alzheimer’s disease has is no cure, medications temporarily slow the worsening of dementia symptoms and help with behavioral problems that may appear. Treatment of Alzheimer’s disease include cholinesterase inhibitors like donepezil, rivastigmine, galantamine; NMDA antagonist like memantine.
There are many clinical trials currently ongoing in Alzheimer’s disease drug development. Some of the most promising trials are studying new ways to treat the disease, such as by targeting specific proteins that are thought to be involved in the development of Alzheimer’s. Other trials are studying new drugs that may help to improve symptoms or slow the progression of the disease. still others are investigating new ways to diagnose Alzheimer’s early, before symptoms begin.
Report Highlights
Global Insight Service’s, Alzheimer’s Disease – Drug Pipeline Landscape, 2022 report provides an overview of the Alzheimer’s Disease pipeline drugs. This report covers detailed insights on Alzheimer’s Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Alzheimer’s Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Purchase your copy now : https://www.globalinsightservices.com/checkout/single_user/GIS31031
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Key Players
• 1st Bio Therapeutics Inc
• 2A Pharma AB
• AB Science
• AbbVie
• Abyssinia Biologics LLC
• AC Immune SA
• Accuitis Pharmaceuticals Inc
• Acelot Inc
• Actinogen Medical Ltd
• Acumen Pharmaceuticals
• ADRx Inc
• Aerobyx LLC
• AIBIOS Co Ltd
• Akome Biotech Ltd
• Alchemab Therapeutics Ltd
Get A Customized Scope to Match Your Need Ask an Expert : https://www.globalinsightservices.com/request-customization/GIS31031
Reasons to buy Alzheimer’s Disease Report:
• Develop comprehensive understanding of market landscape – industry structure, value-chain, key players, trends, drivers, and challenges
• Drive revenue and market-entry strategy by gaining insights into which segments and geographies are largest and likely to grow fastest
• Formulate sales and marketing strategies by gaining understanding of competitors, their positioning, and strengths & weaknesses
• Develop business and M&A strategies through understanding of latest trends and emerging players in the market
• Refine your business plans by understanding impact of disruptions such as Covid-19 and Russia-Ukraine conflict on the market
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/